The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …

As a class, the b-lactams are the most commonly prescribed and clinically dependable
antimicrobials in the United States, representing more than 65% of injected antibiotic …

Over the last decades, there has been a dramatic global increase in multidrug-resistant
(MDR) pathogens particularly among Gram-negative bacteria (GNB). Pseudomonas …

The cephalosporin-β-lactamase-inhibitor-combinations, ceftolozane/tazobactam and
ceftazidime/avibactam, have revolutionized treatment of carbapenem-resistant …

Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range
of serious infections that are often challenging to treat, as this pathogen can express multiple …

Background Antimicrobial resistance is one of the ten major public health threats facing
humanity, especially in developing countries. Identification of the pathogens responsible for …

Due to the overuse of antibiotics, bacterial resistance has markedly increased to become a
global problem and a major threat to human health. Fortunately, in recent years, various new …

Ventilator-associated pneumonia (VAP) in critically ill patients with COVID-19 represents a
very huge global threat due to a higher incidence rate compared to non-COVID-19 patients …

The skin is the largest organ in the human body, acting as a physical and immunological
barrier against pathogenic microorganisms. The cutaneous lesions constitute a gateway for …

Ceftazidime-avibactam (CZA) is the combination of a third-generation cephalosporin and a
new non-β-lactam β-lactamase inhibitor capable of inactivating class A, C, and some D β …